This consensus document provides an update for pathologists and clinicians about the
interpretation of biopsy results and use of this information in the management of …

Leukemia cutis (LC) is a nonspecific term used for cutaneous manifestations of any type of
leukemia. LC has a wide range of cutaneous manifestations, which can make it difficult to …

Immunomodulatory drugs that leverages host immune mechanisms to destroy tumor cells
have been met with great promise in the treatment of cancer. Immunotherapy, targeting …

Answer questions and earn CME/CNE To update the melanoma staging system of the
American Joint Committee on Cancer (AJCC) a large database was assembled comprising> …

Background Whether pembrolizumab given both before surgery (neoadjuvant therapy) and
after surgery (adjuvant therapy), as compared with pembrolizumab given as adjuvant …

Seventy-four shoulders in seventy patients with a history of single or multiple dislocations of
the shoulder demonstrated radiographic evidence of glenohumeral arthropathy. In every …

Immune checkpoint blockade produces clinical benefit in many patients. However, better
biomarkers of response are still needed, and mechanisms of resistance remain incompletely …

Immune checkpoint blockade represents a major breakthrough in cancer therapy; however,
responses are not universal. Genomic and immune features in pretreatment tumor biopsies …

Relatlimab and nivolumab combination immunotherapy improves progression-free survival
over nivolumab monotherapy in patients with unresectable advanced melanoma. We …

Preclinical studies suggest that treatment with neoadjuvant immune checkpoint blockade is
associated with enhanced survival and antigen-specific T cell responses compared with …